Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-02-14 1:38 pm Sale |
2021-12-31 | 13G | ARS Pharmaceuticals, Inc. SPRY |
EcoR1 Capital LLC | 1,060,010 3.000% |
-1,473,625 (-58.16%) |
Filing History |
| 2022-02-10 5:58 pm Purchase |
2022-02-11 | 13G | ARS Pharmaceuticals, Inc. SPRY |
WASATCH ADVISORS LP | 1,775,690 5.100% |
1,775,690 (New Position) |
Filing History |
| 2022-02-09 10:24 am Sale |
2022-02-08 | 13G | ARS Pharmaceuticals, Inc. SPRY |
FMR LLC | 3,753,737 10.701% |
-505,875 (-11.88%) |
Filing History |
| 2022-01-27 3:05 pm Sale |
2021-12-13 | 13D | ARS Pharmaceuticals, Inc. SPRY |
U.S. Venture Partners XII L.P. | 110,120 0.300% |
-2,160,360 (-95.15%) |
Filing History |
| 2021-02-16 4:39 pm Purchase |
2020-12-31 | 13G | ARS Pharmaceuticals, Inc. SPRY |
RA Capital Management, L.P. | 1,742,186 5.000% |
1,742,186 (New Position) |
Filing History |
| 2021-02-16 4:01 pm Purchase |
2020-12-31 | 13G | ARS Pharmaceuticals, Inc. SPRY |
NEXTECH VI ONCOLOGY SCSP | 1,910,029 5.500% |
1,910,029 (New Position) |
Filing History |
| 2021-02-10 09:23 am Purchase |
2021-02-09 | 13G | ARS Pharmaceuticals, Inc. SPRY |
FMR LLC | 4,259,612 12.243% |
818,308 (+23.78%) |
Filing History |
| 2021-02-08 10:33 am Purchase |
2021-02-05 | 13G | ARS Pharmaceuticals, Inc. SPRY |
FMR LLC | 3,441,304 9.891% |
3,441,304 (New Position) |
Filing History |
| 2021-01-04 4:42 pm Purchase |
2020-12-22 | 13G | ARS Pharmaceuticals, Inc. SPRY |
EcoR1 Capital LLC | 2,533,635 7.300% |
2,533,635 (New Position) |
Filing History |
| 2020-12-18 07:22 am Purchase |
2020-12-08 | 13G | ARS Pharmaceuticals, Inc. SPRY |
Boxer Capital LLC | 1,675,377 4.800% |
3 (+0.00%) |
Filing History |
| 2020-12-17 4:37 pm Purchase |
2020-12-08 | 13G | ARS Pharmaceuticals, Inc. SPRY |
Boxer Capital LLC | 1,675,374 4.800% |
1,675,374 (New Position) |
Filing History |
| 2020-12-14 06:05 am Purchase |
2020-12-04 | 13D | ARS Pharmaceuticals, Inc. SPRY |
U.S. Venture Partners XII L.P. | 2,270,480 6.500% |
2,270,480 (New Position) |
Filing History |
| 2020-12-11 4:47 pm Purchase |
2020-12-03 | 13D | ARS Pharmaceuticals, Inc. SPRY |
ORBIMED ADVISORS LLC | 7,788,511 22.400% |
7,788,511 (New Position) |
Filing History |